BioWorld

Feb. 10, 2009

Lundbeck Gains U.S. Foothold in $900M Deal for Ovation

Danish drugmaker H. Lundbeck A/S plans to buy U.S. biotech Ovation Pharmaceuticals in a proposed $900 million deal that would give the Copenhagen-based company access to the U.S. commercial market. (BioWorld Today) Read More

Investors Seeing Positive Side for Biotech in Bleak Economy

Panel: Keep Options Open to Survive Troubled Times

ViroPharma Shares Halved as Maribavir Fails Phase III Trial

Alliance Management Plays Important Role in Avoiding Failure

Lobbying Dynamics Reveal New Trends in Power

Gilded Age Can Be Ushered in by Biopartnered Gene Therapies

Corrections & Clarifications

Dynavax Soars on Possibility of Regulatory Path for Heplisav

Other News To Note

Clinic Roundup

Financings Roundup

Today's news in brief

BioWorld

BioWorld briefs for Dec. 10, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 10, 2025.

Epigenetic technology could eliminate misfolded prion proteins

BioWorld Science

The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Brenig Therapeutics discovers new LRRK2 inhibitors

BioWorld Science

Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...